Banking Recap

M&A Transaction Announced

This record describes a cash-and-stock acquisition falling under the M&A product group, involving Endo Inc. and Mallinckrodt plc. The disclosed value of the transaction is not stated in the source document. The source sentence provided references Endo as the party whose financial advisor's opinion is being discussed, consistent with Endo occupying the target role in this record.

May 8, 2025·SEC EDGAR (S-4)·pending regulatory·cash and stock acquisition

The facts are sourced from an S-4 filing with the SEC via EDGAR, published May 8, 2025. The deal's status is pending regulatory, indicating it had not yet closed as of that filing.

Only one financial advisor is disclosed: Goldman Sachs & Co. LLC, which served as financial advisor to Endo (the target) and is designated lead. The source sentence is drawn from a consent letter, in which the firm consents to the reference to its opinion letter under the caption "Opinion of Endo's Financial Advisor," and is signed on behalf of Goldman Sachs & Co. LLC. No financial advisor is named for the Mallinckrodt (acquirer) side in the facts provided.

No legal advisors are identified in the facts block for either party to this transaction.

Beyond classifying this as a cash-and-stock acquisition, the facts block does not specify the mix of cash versus stock consideration, the exchange ratio, or the aggregate or per-share value of the deal.

Several facts are not disclosed in this record. The transaction's dollar value is not stated. No legal advisors are named for either side. No financial advisor is identified for Mallinckrodt, and no expected closing date is given.